伊马替尼治疗重症COVID-19:一项随机、双盲、安慰剂对照临床试验
这项在荷兰13家教学医院进行的随机、双盲、安慰剂对照试验,纳入400例需补充氧气维持SpO2>94%的住院COVID-19患者,1:1随机接受口服伊马替尼(第0天负荷800mg,第1-9天每日400mg)或安慰剂。主要终点(28天内停用机械通气和补充氧气>48小时的时间)无显著差异(未调整HR 0.95,95%CI 0.76-1.20)。28天死亡率伊马替尼组8% vs 安慰剂组14%(未调整HR 0.51,95%CI 0.27-0.95),调整基线失衡后HR 0.52(95%CI 0.26-1.05)。有创机械通气需求HR 1.07(95%CI 0.63-1.80,p=0.81),有创通气中位时长7天 vs 12天(p=0.0080)。作者认为观察到的生存和有创通气时长获益提示伊马替尼可能带来临床益处,但需进一步研究验证。
要点
- 主要终点未达到:伊马替尼组与安慰剂组停用通气和补充氧气>48小时的时间无显著差异(未调整HR 0.95,95%CI 0.76-1.20)。
- 28天死亡率:伊马替尼组8%(15/197) vs 安慰剂组14%(27/188),未调整HR 0.51(95%CI 0.27-0.95);调整基线失衡后HR 0.52(95%CI 0.26-1.05)。
- 有创机械通气需求两组无显著差异:HR 1.07(95%CI 0.63-1.80,p=0.81)。
- 有创机械通气中位时长:伊马替尼组7天(IQR 3-13) vs 安慰剂组12天(IQR 6-20),p=0.0080。
- 至少1次≥3级不良事件:伊马替尼组46%(91/197) vs 安慰剂组44%(82/188);安全性评估未发现与伊马替尼相关的不良事件。
适用人群与场景
- 纳入:年龄≥18岁、RT-PCR确诊SARS-CoV-2感染、需补充氧气维持外周血氧饱和度>94%的住院COVID-19患者。
- 排除:严重既存肺部疾病、既存心力衰竭、过去12个月内接受过血液系统或非血液系统恶性肿瘤积极治疗、血细胞减少、或同时使用已知与伊马替尼强相互作用的药物。
处置流程与药物剂量
- 伊马替尼组:口服伊马替尼,第0天负荷剂量800 mg,第1-9天每日400 mg。
- 对照组:口服安慰剂。
- 主要终点评估:28天内停用机械通气和补充氧气持续>48小时且存活的时间。
研究设计与关键结果
- 研究设计:随机、双盲、安慰剂对照临床试验,在荷兰13家学术和非学术教学医院进行;2020年3月31日至2021年1月4日筛查805例,400例符合条件并随机分配至伊马替尼组(n=204)或安慰剂组(n=196)。
- 分析人群:385例(96%)接受至少一剂研究药物,纳入改良意向治疗人群;中位年龄64岁(IQR 56-73)。
- 主要终点:停用通气和补充氧气>48小时的时间两组无显著差异(未调整HR 0.95,95%CI 0.76-1.20)。
- 28天死亡率:伊马替尼组8%(15/197) vs 安慰剂组14%(27/188),未调整HR 0.51(95%CI 0.27-0.95);调整基线失衡(性别、肥胖、糖尿病、心血管疾病)后HR 0.52(95%CI 0.26-1.05)。
- 有创机械通气需求:伊马替尼组 vs 安慰剂组 HR 1.07(95%CI 0.63-1.80;p=0.81)。
- 有创机械通气中位时长:伊马替尼组7天(IQR 3-13) vs 安慰剂组12天(IQR 6-20),p=0.0080。
- 不良事件:至少1次≥3级不良事件伊马替尼组46%(91/197) vs 安慰剂组44%(82/188);安全性评估未发现与伊马替尼相关的不良事件。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照临床试验。
- 局限:研究未达到主要终点;作者指出观察到的生存和有创通气时长获益需进一步研究验证。
对床旁实践的改变
- 作者认为,观察到的生存获益(调整基线失衡后有所减弱)和有创机械通气时长缩短提示伊马替尼可能为住院COVID-19患者带来临床益处,但需进一步研究验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The major complication of COVID-19 is hypoxaemic respiratory failure from capillary leak and alveolar oedema. Experimental and early clinical data suggest that the tyrosine-kinase inhibitor imatinib reverses pulmonary capillary leak.
METHODS: This randomised, double-blind, placebo-controlled, clinical trial was done at 13 academic and non-academic teaching hospitals in the Netherlands. Hospitalised patients (aged ≥18 years) with COVID-19, as confirmed by an RT-PCR test for SARS-CoV-2, requiring supplemental oxygen to maintain a peripheral oxygen saturation of greater than 94% were eligible. Patients were excluded if they had severe pre-existing pulmonary disease, had pre-existing heart failure, had undergone active treatment of a haematological or non-haematological malignancy in the previous 12 months, had cytopenia, or were receiving concomitant treatment with medication known to strongly interact with imatinib. Patients were randomly assigned (1:1) to receive either oral imatinib, given as a loading dose of 800 mg on day 0 followed by 400 mg daily on days 1-9, or placebo. Randomisation was done with a computer-based clinical data management platform with variable block sizes (containing two, four, or six patients), stratified by study site. The primary outcome was time to discontinuation of mechanical ventilation and supplemental oxygen for more than 48 consecutive hours, while being alive during a 28-day period. Secondary outcomes included safety, mortality at 28 days, and the need for invasive mechanical ventilation. All efficacy and safety analyses were done in all randomised patients who had received at least one dose of study medication (modified intention-to-treat population). This study is registered with the EU Clinical Trials Register (EudraCT 2020-001236-10).
FINDINGS: Between March 31, 2020, and Jan 4, 2021, 805 patients were screened, of whom 400 were eligible and randomly assigned to the imatinib group (n=204) or the placebo group (n=196). A total of 385 (96%) patients (median age 64 years [IQR 56-73]) received at least one dose of study medication and were included in the modified intention-to-treat population. Time to discontinuation of ventilation and supplemental oxygen for more than 48 h was not significantly different between the two groups (unadjusted hazard ratio [HR] 0·95 [95% CI 0·76-1·20]). At day 28, 15 (8%) of 197 patients had died in the imatinib group compared with 27 (14%) of 188 patients in the placebo group (unadjusted HR 0·51 [0·27-0·95]). After adjusting for baseline imbalances between the two groups (sex, obesity, diabetes, and cardiovascular disease) the HR for mortality was 0·52 (95% CI 0·26-1·05). The HR for mechanical ventilation in the imatinib group compared with the placebo group was 1·07 (0·63-1·80; p=0·81). The median duration of invasive mechanical ventilation was 7 days (IQR 3-13) in the imatinib group compared with 12 days (6-20) in the placebo group (p=0·0080). 91 (46%) of 197 patients in the imatinib group and 82 (44%) of 188 patients in the placebo group had at least one grade 3 or higher adverse event. The safety evaluation revealed no imatinib-associated adverse events.
INTERPRETATION: The study failed to meet its primary outcome, as imatinib did not reduce the time to discontinuation of ventilation and supplemental oxygen for more than 48 consecutive hours in patients with COVID-19 requiring supplemental oxygen. The observed effects on survival (although attenuated after adjustment for baseline imbalances) and duration of mechanical ventilation suggest that imatinib might confer clinical benefit in hospitalised patients with COVID-19, but further studies are required to validate these findings.
FUNDING: Amsterdam Medical Center Foundation, Nederlandse Organisatie voor Wetenschappelijk Onderzoek/ZonMW, and the European Union Innovative Medicines Initiative 2.
参考来源
- Aman J, Duijvelaar E, Botros L, et al. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respir Med. 2021. PMID: 34147142. doi:10.1016/S2213-2600(21)00237-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。